U.S. Patent Disclosures
Tuesday, October 18, 2011
Lpath Inc., of San Diego, received U.S. Patent Nos. 8,025,877, and 8,026,342, which claim methods and composition of matter for its anti-sphingosine-1-phosphate antibody, sonepcizumab, the active component in the firm's lead compounds iSONEP and ASONEP.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.